What is PE-22-28?
PE-22-28 is a seven-amino-acid peptide. It is a shortened version of spadin, a natural peptide cut from the propeptide of the protein sortilin, which blocks the TREK-1 potassium channel in the brain. PE-22-28 is the smallest fragment found to keep spadin’s TREK-1 blocking activity. In the study that described it, it was more stable than spadin and showed antidepressant-like effects in mice (Djillani et al., Frontiers in Pharmacology, 2017).
PE-22-28 product specifications
- Compound: PE-22-28 (shortened spadin analog)
- Sequence: Gly-Val-Ser-Trp-Gly-Leu-Arg (GVSWGLR, 7 amino acids)
- Target studied: TREK-1 (K2P2.1) potassium channel
- Vial size: 10mg
Regulatory status
PE-22-28 is not an approved medicine in the US, UK, EU or Canada and has no published human clinical trials. This product is sold for laboratory research use only.
Related research peptides
- Selank is another short peptide studied in neuroscience research.
- P21 is a peptide studied in mouse models of neurodegeneration.
Available size: 10mg
PE-22-28 is supplied in 10mg vials as a dry (lyophilised) powder. The figure is the total amount of peptide in the vial, not a concentration.
Handling and research-use notice
Store and handle this material as stated on the label and certificate of analysis for your batch; see our guide to storing research peptides. This product is sold for laboratory research use only. It is not a medicine or supplement and is not for human or veterinary use.
